• To evaluate the safety and efficacy of mitral valve repair for moderate ischemic mitral regurgitation.
  

• To assess the impact of CABG alone and CABG plus mitral valve repair on the target population in the following areas: cardiac performance, mortality, adverse events, quality of life, functional status, presence and severity of MR, health resource use
  

Procedure: CABG
N/A
Procedure: MVR
N/A

The research activities in this protocol are meant to support the multicenter CSTN (Cardiothoracic Surgical Trials Network) protocol, Surgical Interventions for Moderate Ischemic Mitral Regurgitation which is being conducted at Suburban Hospital. This protocol deals with only the research studies being conducted at the NIH Clinical Center. Patients undergoing surgery at the NIH Heart Center at Suburban Hospital will be recruited for this study. The Principal Investigator there is Dr. Keith Horvath and the majority of procedures will be performed at Suburban Hospital and monitored by the Suburban Hospital Institutional Review Board (IRB). The preoperative and follow-up echo and cardiopulmonary stress tests on enrolled patients, however, will be performed at the NIH Clinical Center and will be described in detail by this protocol. In addition, to ensure consistency of data quality, NIH staff will be assisting with the acquisition of the intro-operative echo studies at Suburban Hospital.

The overall objective of this study is to evaluate the safety and efficacy of mitral valve repair (MVR) for moderate ischemic mitral regurgitation.

Specifically, this study compares mitral valve repair combined with coronary artery bypass grafting (CABG) to coronary artery bypass grafting alone in this patient population. Patients will be randomly assigned (1:1) to CABG + MVR or CABG alone.